OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial
Condition.
On May5, 2017, Ocular Therapeutix,Inc. (the Company) announced
its financial results for the quarter ended March31, 2017. The
full text of the press release is furnished as Exhibit99.1 to
this Current Report on Form8-K and is incorporated herein by
reference.
The information in this Current Report on Form8-K, including
Exhibit99.1 attached hereto, is furnished to comply with Item2.02
of Form8-K, and shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
Item9.01. Financial Statements and
Exhibits.
(d) Exhibits:
|
99.1 |
Press Release of Ocular Therapeutix,Inc., dated May5, 2017 |
About OCULAR THERAPEUTIX, INC. (NASDAQ:OCUL)
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD). OCULAR THERAPEUTIX, INC. (NASDAQ:OCUL) Recent Trading Information
OCULAR THERAPEUTIX, INC. (NASDAQ:OCUL) closed its last trading session 00.00 at 9.10 with 484,197 shares trading hands.
